Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer

PURPOSE: Ceralasertib is a potent and selective oral inhibitor of the serine/threonine protein kinase ataxia telangiectasia and Rad3-related (ATR) protein. PATIENTS AND METHODS: Eligible patients with solid tumors, enriched for melanoma, received ceralasertib in combination with a fixed dose of pacl...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Seung Tae, Smith, Simon A., Mortimer, Peter, Loembé, Arsene-Bienvenu, Cho, Heejin, Kim, Kyoung-Mee, Smith, Claire, Willis, Sophie, Irurzun-Arana, Itziar, Berges, Alienor, Hong, Jung Yong, Park, Se Hoon, Park, Joon Oh, Park, Young Suk, Lim, Ho Yeong, Kang, Won Ki, Kozarewa, Iwanka, Pierce, Andrew J., Dean, Emma, Lee, Jeeyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8974415/
https://www.ncbi.nlm.nih.gov/pubmed/33975862
http://dx.doi.org/10.1158/1078-0432.CCR-21-0251

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8974415/
https://www.ncbi.nlm.nih.gov/pubmed/33975862
http://dx.doi.org/10.1158/1078-0432.CCR-21-0251

Ejemplares similares